Moricizine Hydrochloride (EN 313) is an orally active class I antiarrhythmic agent that reduces the maximum rate of phase 0 depolarisation; increases the repolarisation rate of phases 2 and 3, reduces the duration of action potentials and reduces the effective non-response period.